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The detection and quantitation of exogenously administered biological 
macromolecules (e.g. vaccines, peptide and protein therapeutics) and their 
metabolites is frequently complicated by the presence of a complex endogenous 
mixture of closely related compounds. We describe a method that incorporates 
stable isotope labeling of the compound of interest allowing the selective 
screening of the intact molecule and all metabolites using a modified precursor 
ion scan. This method involves monitoring the low molecular weight fragment 
ions produced during MS/MS that distinguish isotopically labelled material from 
related endogenous compounds. All isotopically labelled substances can be 
selected using this scanning technique for further analysis whilst other 
unlabelled and irrelevant substances are ignored. The potential for this 
technique to be used in metabolism and pharmacokinetic experiments is 
discussed with specific examples looking at the metabolism of α-synuclein in 
serum and the brain. 
 
It is often necessary to distinguish a target peptide from a mixture of other closely 
related species within a wide range of analyte concentrations. Mass spectrometry is 
frequently the method of choice for such analyses as it can selectively identify 
peptides by their nominal (precursor ion) mass and/or by using their fragment ion 
(product ion) spectra1. However the complexity of many biological samples often 
results in the simultaneous production of multiple precursors, even with on-line 
separation techniques such as during LC-MS. Most modern instruments can readily 
manage this situation and given sufficient time can systematically attempt to 
characterize one ion after another until all the available components are sampled.  The 
disadvantage of this technique is the time taken to analyse each precursor, which in 
the case of very complex samples may be longer than the analyte is available (e.g. 
during the duration of a chromatographic peak in which the analyte(s) are contained 
during an LC-MS experiment). 
 
There are two targeted mass spectrometry techniques to more specifically detect 
specific peptides from a mixture. The first is “single ion monitoring" (SIM) or 
"multiple reaction monitoring" (MRM) where the mass spectrometer is configured to 
only detect molecules of a defined precursor m/z (mass), ignoring or excluding all 
others, allowing molecules of known mass to be identified with very high sensitivity2. 
In complex mixtures it is particularly desirable to use additional information about the 
targeted molecule to identify it from closely related species of similar or identical 
mass. Thus the mass spectrometer is configured to monitor for the presence of a 
specific product ion that is formed by the fragmentation of a targeted precursor ion; 
for example monitoring the intensity of a specific b ion formed by the fragmentation 
of a known peptide precursor.  
 
The second technique for detection of target compounds in a complex mixture is 
called "precursor ion scanning" or "parent ion scan". In this instance prior knowledge 
of the molecule may not extend to knowledge of the precursor mass, but the molecule 
may be known to contain a certain component that would result in the presence of a 
diagnostic product ion. For example, Wilm et al.3 report the detection of peptides at 
low femtomole levels using precursor ion scans by monitoring for the presence of the 
Leucine/Isoleucine immonium ions. They also demonstrated the selective detection of 
different subsets of tryptic peptides by using the y1 ion corresponding to respective 
Arginine or Lysine C-terminal residues, and the selective detection of 
phosphopeptides from a mixture by targeting the ion corresponding to PO3- fragment 
(m/z -79). These examples highlight the utility of this well established technique4-7 to 
perform targeted proteomic analysis on classes of peptides based on their generation 
of a unique fragment ion during MS/MS. 
 
Both precursor scanning and SIM/MRM are limited by the necessity to have 
knowledge of the target precursor mass and/or the product ion mass for the class of 
molecules or the molecule of interest1. In a complex biological system often it is 
impossible to predict the mass of the natural form of a target peptide. This may be due 
to post-translational modification of the peptide, natural proteolytic processing or 
metabolism of the peptide from the parent biomolecule. This problem can be 
overcome to some extent by performing multiple precursor scans or MRM transitions, 
however the peptides "discovered" will always be limited by the assumptions 
regarding precursor m/z or product ion masses monitored in the respective 
experiments. Also, in many instances the total number of potential metabolites is so 
large that it becomes impractical to monitor all the possible MRM transitions to cover 
the candidate metabolites. It is therefore desirable to have an analytical technique 
which can selectively screen out target peptides from a complex mixture, in real time, 
that does not require the same assumptions as an MRM or precursor scan.  
   
One approach to overcoming this problem has involved the use stable isotope 
labelling to enable the identification of naturally processed forms of proteins in 
complex biological mixtures. For example the identification of peptide epitopes 
derived from isotopically labelled protein antigens8. In this approach a search engine 
is used to retrospectively interrogate the data to identify isotopically labelled (i.e. 
antigen derived) peptides that were observed in the first analytical run and then a 
second experiment is used to sequence the target peptides using an inclusion list for 
MS\MS analysis. The necessity to use multiple LC runs for the same sample makes 
this approach cumbersome and restricts identification of low abundance peptides. For 
very complex samples there is also the complication of co-eluting isobaric peptides 
that would interfere with the identification process.  
 
Here we describe a variation of a precursor ion scan in conjunction with stable isotope 
labelling that allows real time discrimination of isotopically labelled material and 
triggers further MS/MS analysis for the identification and characterisation of these 
species.  In this instance we assume that a target peptide derived from a uniformly 15N 
labelled protein will produce one or more characteristic fragment ions, such as 15N 
containing immonium ions, in the low mass region of the product ion spectra9, 10. 
These ions can be used as the diagnostic ions for a precursor scan. We have termed 
this technique NIIPe, 15N Immonium Ion Precursor scanning. We have shown that 
using this technique we can successfully screen 15N labelled peptides from a complex 
mixture of more abundant unlabelled peptides. This technique will have application in 
any mass spectrometry experiment where the prerequisite knowledge for an MRM or 
precursor scan cannot be met. The technique also has the further advantage that 
peptides from the original protein can still be identified irrespective of what types of 
processing or modification the peptide underwent affording new levels of coverage in 
DMPK and other monitoring technologies.  
 
Results 
The principal of precursor ion scanning is very useful as it screens out those ions that 
do not meet the selection criteria. All that is required is a suitable diagnostic ion that 
can be used to define the presence of the target compound or class of compounds. We 
and others3, 11 have shown that the low mass region of the product ion spectrum 
contains ions that could be used to distinguish different classes of peptides. We 
further elaborate on this idea by introducing the concept that for 15N labelled peptides, 
diagnostic low mass ions can be used to distinguish these isotopically labelled species 
from endogenous peptides. In particular, all immonium ions9 contain at least one 
nitrogen and hence all immonium ions formed from a 15N labelled peptide will display 
a mass shift of at least 1amu. A calculation of the mass of all the 15N immonium ions 
compared to all the unlabelled immonium ions revealed that, with the exception of 
15N Leu/Ile overlapping with unlabelled Asn, they produced unique fragment ions 
(Table 1). Moreover, we have also empirically observed and validated several 
immonium ion related species that produce distinctive reporter ions for multiple 15N-
labelled amino acid residues (Table 1). Indeed, MS\MS of 15N labelled peptides 
produced distinctive product ion species (Fig. 1) and highlight the potential use of one 
or more 15N immonium or related ions as targets for a precursor scan that would 
selectively screen out 15N peptides from endogenous peptides. 
 
A 15N precursor ion scan can be performed using any triple quadrupole mass 
spectrometer which is able to target a single fragment ion and then scan for precursor 
masses that give rise to the target ion. Thus 15N peptides could be screened from a 
mixture by using, for example, the mass of the 15N immonium ion of valine at m/z 73. 
As shown in Figure 2, a series of 15N targeted precursor scans successfully screened 
15N labelled α−synuclein peptides from a mixture also containing unlabelled BSA 
tryptic peptides. The full complexity of the peptide mixture is revealed by the base 
peak chromatogram representation of the LC-MS experiment (Fig 2A). As expected 
each of the three scans screened out a different subset of α−synuclein peptides and 
ignored most of the BSA peptides (Fig. 2B-D). The precursor scan of 73 detected 
peptides that generated a 15N-Valine immonium ion (L3-5, L8, L10, L12: supplementary 
Table 1), representing all but two valine containing peptides present in the sample. 
The peak marked with an asterisk most likely represents the L1 fragment however 
MS/MS verification was not possible. An L13 fragment was not visualised using the 
73 precursor ion scan presumably as a result of context dependent valine immonium 
ion formation9 and the failure of this fragment to produce an intense 73 amu 
diagnostic ion.  The precursor scan for m/z 103 (Fig 2C) selected peptides containing 
glutamate, glutamine and lysine due to the overlap between the immonium ions 
derived from Glu and Gln and a Lysine derived related low mass ion. This overlap in 
diagnostic ions allowed identification of all anticipated Lys C peptides derived from 
α-synuclein (i.e. peptides >5aa in length and not including the large C-terminal 
fragment which is outside the mass range in these experiments – see Supplementary 
Table 1) and as such was the best scanning functionality for this particular example. 
Finally a precursor scan of 131 representing the Lysine immonium ion for which all 
Lys C peptides should generate a peak identified all but one anticipated peptide (L6) 
again presumably due to failure of this peptide to yield a 131 immonium ion due to 
sequence context. Of note this peptide generated a strong 103 precursor scan signal. 
An example of the MS/MS characterisation of the L4 peptide is shown in Fig 2E. 
Importantly any falsely selected BSA peptides were readily discriminated once the 
inappropriately triggered MS/MS spectrum was interrogated due to the unique nature 
of 15N-fragment ions. Across the three individual precursor scans only 8 BSA peptides 
triggered an MS/MS experiment while there were 26 α−synuclein selections that 
covered all of the expected peptides. These data highlight the utility of using more 
than one precursor scan despite known sequence elements of the peptides, for instance 
the combination of 131 and 103 identified all anticipated α-synuclein Lys C peptides. 
 
In the example above 15N labelled peptides were screened out using a single precursor 
scan. However, not all naturally processed peptides will contain the specific amino 
acid used in the precursor ion scan even when overlapping reporter ions, such as the 
m/z 103 ion, are used. In addition to the 103 reporter ion, several other low mass ions 
have been observed in the fragmentation spectra of 15N-labelled peptides that are 
shared between more than one amino acid residue allowing further potential coverage 
of peptides in a single experiment (Table 1). Therefore by combining highly specific 
immonium ions and related ions it is possible to obtain high sequence coverage in a 
precursor scan experiment. Moreover, using an AB SCIEX 4000 QTRAP mass 
spectrometer, which can simultaneously monitor a maximum of 4 precursors, we 
designed multiple precursor scan experiments using low mass target ions that 
corresponded to amino acids that were known to produce immonium or related low 
mass ions9 and were distributed as regularly as possible throughout the target protein 
sequence.  
 
In order to fully assess the feasibility of using multiple precursor scans the complexity 
of the sample was increased by combining 10 pmol of a dual trypsin and V8 protease 
digest of 15N labelled dihydropicolinate synthase (DHDPS) with an unlabelled sample 
containing > 5000 peptides at varying concentrations. This unlabelled sample was 
prepared by acid extraction of cell surface peptides from murine splenocytes, 
equivalent to 40ug of total peptide.  In this experiment unlabelled peptide was 
deliberately added in order to try and make it more difficult to specifically select 15N 
peptides over the background noise of the unlabelled peptides. A multiple precursor 
scan targeting m/z 71 (P, D, N), 73 (V, I), 85 and 103 (K,E,Q) was used. As shown in 
Figure 3, precursors of m/z 491 (red Proline immonium ion, Aspartic acid and 
Asparagine immonium related ions) and 681.2 (green Valine immonium ion, 
Isoleucine immonium related ion) identified DHDPS peptides that were not readily 
detectable by regular MS, whilst the third precursor identified at 735.5 was abundant 
in both normal MS and in the NIIPe scan. Another abundant species at 603.1 was 
manually selected for MS/MS and shown to represent an unlabelled peptide. Thus, the 
multiple precursor scan was able to selectively filter out labelled peptides in 
preference to the unlabelled peptides. 
 
The data presented in Figures 1-3 collectively highlight the selectivity of NIIPe and its 
ability to identify isotopically labelled peptides from complex mixtures even when 
effectively undetectable by conventional untargeted LC-MS/MS. We next sought to 
compare NIIPe to direct LC-MS/MS analysis of a complex mixture. A small amount 
(5 pmol) of 15N DHDPS trypsin digest was added to a peptide extract from murine 
splenocytes (as above) in order to create a mixture in which the peptides of interest 
were at concentrations that prevented untargeted LC-MS/MS detection. This mixture 
was then divided into aliquots which were run as either NIIPe scans or regular 
MS/MS acquisitions with identical LC methodologies on a 4000 QTRAP instrument. 
Analysis of this mixture using normal LC-MS/MS only identified three peptides 
originating from the labelled DHDPS following exhaustive manual interrogation of 
the raw MS/MS data. In contrast in the precursor scanning experiments DHDPS 
peptides were detected and selected for MS/MS based sequencing without manual 
intervention, allowing highly specific and rapid identification of the target peptides. 
Thus five peptides derived from the labelled DHDPS peptides were specifically 
detected and sequenced in the multiple precursor scan. In order to eliminate the 
impact of the relatively long cycle time (>20s) for the multiple precursor scan, the 
same sample was analysed in individual precursor scan experiments. This allowed up 
to nine DHDPS peptides to be identified (Table 2). This time penalty was partially 
overcome in some experiments by selecting low mass target ions that cover more than 
one amino acid due to overlap between classical immonium ions and related low mass 
ions from other amino acids9, 10 (Table 1). 
 
Potential applications for this methodology include protein metabolism, 
bioequivalence and DMPK analyses12-15. In order to demonstrate the ability of NIIPe 
to facilitate such analyses we examined the metabolism of exogenously administered 
15N-labelled α-synuclein in serum and in murine brain extracts. In these experiments, 
5 nmol of 15N α-synuclein was added to an equal volume of mouse serum or crude 
murine brain homogenate. Proteins were precipitated and the remaining soluble 
peptides analysed by mass spectrometry. As demonstrated in Figure 4, NIIPe not only 
demonstrated differences in metabolism of α-synuclein in the brain and serum it 
allowed the identification of novel peptides derived from this protein as a result of 
tissue specific endo- and exopeptidase activities (Reilly et al., manuscript in 
preparation). This differential production of peptide metabolites included differences 
in the generation of predominantly C-terminal peptides; with KNEEGAPQEGILED 
and EGYQDYEP found uniquely in the brain extract and IAAAT and 
VTGVTAVAQK peptides found uniquely in serum. Significantly no endogenous α-
synuclein peptides were observed despite its high abundance in the brain extract. 
 
Discussion 
We have demonstrated that the use of 15N immonium ions as targets for a precursor 
scan can be used to selectively screen out 15N labelled peptides from a mixture of 
other unlabelled peptides. Although some 15N-labelled peptides can be detected using 
standard LC-MS/MS experiments, they were only identified following exhaustive 
manual interrogation of the several thousand MS/MS spectra recorded in the 
untargeted analysis of a complex mixture. In contrast the NIIPe scan experiment 
selected far fewer precursors for subsequent MS/MS analysis. Thus NIIPe 
demonstrated superior sensitivity and specificity (Figure 3 and Table 2) both in 
precursor selection and validation, since MS/MS of 15N-labelled material is easily 
distinguished from inadvertently triggered MS/MS spectrum of unlabelled material 
post data acquisition. Simultaneous monitoring of multiple diagnostic low mass ions 
allowed the detection of peptides in complex mixtures that would otherwise be hidden 
by the complexity of the sample. As the technology and instrumentation continues to 
develop, we anticipate the capacity to monitor the entire low mass region (50-300 
AMU) for all possible diagnostic ions for the isotopically labelled material. Such 
analysis will allow the detection of all 15N precursors for subsequent MS/MS 
characterisation. This ability to broadly scan the low mass region would also allow 
multiplexing of the experiment to encompass other stable isotope labels. An 
additional benefit of this would be that by using multiple target ions you reduce the 
possibility of false selection due to chemical noise, difference in peptide 
concentrations in the sample, or other contaminants in the sample. The technique is 
also not simply restricted to immonium ions since other low mass ions that display a 
diagnostic change in mass for a labelled peptide can be used, for example y1. 
Moreover the addition of any stable isotope (13C, 2H, etc) will produce diagnostic 
fragment ions allowing additional scrutiny of other classes of compounds including 
RNA and DNA and artificially introduced chemical entities such as spacer groups or 
PEG. 
 
The technique is particularly useful for the analyses of unanticipated species where 
other techniques such as MRM or targeted analyses are not feasible. The workflow 
provides new avenues for ADME and DMPK studies16-21 allowing deeper coverage of 
metabolites and the capacity to monitor rare species directly ex vivo. Thus, this 
method does not replace MRM or precursor scanning techniques; instead it is a 
method that can be used when the assumptions required for the former two techniques 
cannot be met, providing unparalleled depth of metabolite identification. In the 
example shown in this manuscript several differentially processed peptides derived 
from α-synuclein were identified in brain and serum extracts. α-synuclein is a small 
heat stable protein found associated with amyloid deposits in neurodegenerative 
diseases such as Parkinson’s disease22 and Alzheimer’s disease23. Of interest one of 
the peptides identified in serum VTGTAVAQK is derived from the fibrillogenic 
hydrophobic core of α-synuclein that has been shown to facilitate fibril formation in 
other studies24. Several other applications are also under investigation in our 
laboratories. These include the identification and characterisation of peptide epitopes 
derived from an exogenous isotope labeled antigen after processing by antigen 
presenting cells25 and protein shedding from transplanted tissues and tumor grafts as 
sources of biomarkers and therapeutic targets. Once results from the NIIPe scan are 
determined further inroads into sensitivity and throughput can be afforded by linking 
the NIIPe discovery data back to create a set of MRM’s for quantitation or further 
high throughput analysis using workflows such as scheduled MRMs26-28 on labelled 




Sample preparation.  15N α−synuclein was a gift from Dr Roberto Cappai, 
Department of Pathology, University of Melbourne. 15N DHDPS was a gift from Dr 
Renwick Dobson, Department of Biochemistry and Molecular Biology, University of 
Melbourne. BSA was from Sigma-Aldrich (St. Louis, MO). Proteins were 
resuspended in 50 mM TEAB and digested for 24hr at 37°C, using proteomics grade 
Trypsin, LysC or endoprotease GluC at a ratio of 50:1 by mass. The mouse thymus 
MHC peptide mixture was prepared by acid extraction as described elsewhere25, 29. 
Trypsin digested 15N DHDPS was spiked into 40μg of mouse thymus MHC peptide 
lysate. For α-synuclein experiments 5 nmol of 15N α-synuclein was added to 1ml of 
neat serum or 1ml of crude brain homogenate (1 mouse brain homogenised [mortar 
and pestle] in TBS to a volume of 1 ml). Proteins were precipitated by the addition of 
4 volumes of 20% trichloroacetic acid on ice. Protein precipitate was removed by 
benchtop centrifugation at 16000×g and the remaining supernatant analysed by mass 
spectrometry. 
Mass Spectrometry; QTOF analysis of the low mass region for 15N α−synuclein was 
carried out using an AB SCIEX QSTAR Elite Hybrid LC-MS/MS coupled with an 
Eksigent Tempo™ nanoflow LC. 10 pmol of 15N α−synuclein LysC digest was 
loaded onto a 300μm C18 trap column and further separated by a 75μm x 10cm C18 
column (SGE Australia) using a 45 min, 2-60% Acetonitrile/ 0.1% Formic acid 
gradient. Data dependent acquisition was performed on ions between the mass range 
of 370 - 1400 Da with an intensity threshold of >20 cps and product ion scans that 
covered the mass range of 68 -1800 Da 
 
4000 QTRAP experiments.  Samples were loaded onto a 300μm x 10mm C18 trap 
column and further separated by a 300μm x 10cm C18 column (SGE Australia) using 
a 75 min, linear 2-60% Acetonitrile/0.1% Formic acid gradient delivered by a Dionex 
UltiMate 3000 capillary HPLC system at 8μl/min. Eluting peptides were analysed 
using an AB SCIEX 4000 QTRAP instrument fitted with a Turbo V ion source. For 
the immonium ion precursor scans, multiple 6 second precursor scans were performed 
using a collision energy ramp of 25 to 50 eV for a mass range of 400-1000 Da with a 
step size of 1.0 amu. Q1 resolution was set to low and Q3 was set to unit resolution. 
Automated MS/MS selection was performed with an intensity threshold of 1.00 cps 
and triggered three enhanced product ion scans. These were performed using Q0 
trapping and rolling collision energy, scanning the mass range of 69-1500 Da with a 
LIT fill time of 40ms. A single MS scan was also looped into the method to provide 
more information for later analysis of the precursors available for selection. Total 
cycle time was ~28s for 4 precursor or ~20s for a triple precursor and ~15s for a 
double precursor scan. Conventional LC-MS/MS experiments using the 4000 Q 
TRAP were performed using the same chromatographic and ion source parameters as 
the precursor scan. A survey scan monitored masses from m/z 400 to 1600 and 
automated MS/MS was employed to target the top 2 precursors per scan, using rolling 
collision energy, Q0 trapping, intensity threshold 1,000 cps, excluding former target 
ions for 60s, LIT fill time 50ms. 
 
Data analysis. All the mass spectrometry data sets were analysed manually and 
peptides sequenced by de novo techniques. This was because of the inability of the 
available software tools to reliably work with 15N labelled peptides.  
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Figure 1: The low mass product ions for unlabelled and 15N labelled peptides. (A) 
spectrum for the low mass product ions for the α−synuclein peptide EGVLYVGSK. 
When the same peptide is 15N labelled there is a distinct shift in the low mass product 
ions as shown in (B) 
 
Figure 2: Precursor ion scanning for 15N immonium ions. A 1mg per /ml BSA trypsin 
digest was spiked with and equal volume of 1mg/ml 15N α-synuclein LysC digest. A) 
The base peak chromatogram for the mixture indicating a complex mix of the two sets 
of peptides. The automated data acquisition software selected ions from both BSA and 
a-synuclein for MS/MS analysis. Using the same sample three separate precursor ion 
scan experiments were used to specifically target 15N labeled peptides via low mass 
ions characteristic of a 15N labeled amino acid. The masses selected were m/z 73 for 
15N Valine; 103 corresponding to ions for 15N Glutamate, Glutamine and Lysine; and 
131 corresponding to 15N Lysine. B), C), and D) show the TIC of the product ion 
scans for each experiment. Peptides derived from 15N α-synuclein are indicated as Ln 
where n is the LysC peptide number (see Supplementary Table 1). Falsely selected 
peaks are indicated with an asterisk. Small peaks with no annotation could not be 
identified due to poor fragmentation spectra. As expected, each of the three precursor 
scans identified different subsets of the 15N α-synuclein peptides demonstrating that a 
standard precursor ion scan would not identify all of the possible peptides in the mix. 
Hence it is necessary to monitor as many 15N immonium ions as possible to ensure the 
best chance of identifying all of the target peptides. E) The MS/MS spectrum of the 
fourth 15N α-synuclein LysC peptide (L4, EGVVAAAEK) as captured by the m/z 131 
precursor scan    
 
Figure 3: Scanning 15N labelled peptides out of a complex mixture. Approximately 10 
pmol of 15N DHDPS was digested with trypsin and added to a very complex mixture 
of unlabelled peptides (~40μg of MHC peptide preparation). Half of this sample was 
then analysed by regular LC-MS/MS and the other half by a multi precursor ion scan. 
(A) Shows the mass spectrum of all peptides entering the mass spectrometer for the 
time point 53.4 min, indicating the presence of several abundant peptides. This 
enhanced mass spectral survey scan was looped into the precursor ion scan 
experiment to provide detailed untargeted information about the peptide mixture (B) 
Shows the precursor scan results corresponding to the same time point. Overlayed are 
the intensity of ions for the 15N masses 71 (red), 73 (green), 85 (blue) and 103 (black). 
The three major peaks in the precursor profile each correspond to 15N DHDPS 
peptides that were consequently selected by the precursor scan for further MSMS 
analysis as shown in C) 15N SDFHHHD, D) 15N HWDJHSKLG, and E) 15N 
KMFJDSFGS. The final panel F) shows the ms/ms spectrum for the unlabelled 
peptide SDJSFGDGHK. This peptide with a precursor mass of 603.1 is observed in 
panel A) however it was ignored by the precursor scan experiment. The data shown in 
F) was extracted from the previous LC-MS/MS run on the same sample.   
 
Figure 4: Using NIIPe to search for peptides of 15N α-synuclein after incubation for 5 
min in serum or brain extract. 5 nmol of 15N α-synuclein was added to 1ml of neat 
serum or 1ml of crude brain homogenate (1 mouse brain homogenised in TBS to a 
volume of 1 ml). Proteins were precipitated by TCA and then 5μl of the remaining 
soluble fraction was analysed using m/z 85 and 73 as target ions for a dual precursor 
scan. The TIC for the precursor scan for m/z 85 is shown for the brain (blue) and the 
serum sample (red). A number of 15N labelled peptides were screened from the 
samples including the two peptides shown in the inset. A) is the 15N labelled peptide 
IAAAT while B) the second peptide is VTGVTAVAQK.  
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Residue 3-letter code  1-letter code Immonium ion* Related ions* 15N Immonium ion* Observed 15N Related ions* 
Alanine, Ala A 44  45  
Arginine, Arg R 129 59, 70, 73, 87, 100, 112 133  
Asparagine, Asn N 87 70 89 71 
Aspartic acid, Asp D 88 70 89 71 
Cysteine, Cys C 76  77  
Glutamic acid, Glu E 102  103  
Glutamine, Gln Q 101 56, 84, 129 103 85,131 
Glycine, Gly G 30  30  
Histidine, His H 110 82, 121, 123, 138, 166 113  
Isoleucine, Ile I 86 44, 72 87 73,45 
Phenylalanine, Phe F 120 91 121  
Proline, Pro P 70  71  
Leucine, Leu L 86 44, 72 87 45,73 
Lysine, Lys K 101 70, 84, 112, 129 103 131, 85 
Methionine, Met M 104 61, 70 105  
Serine, Ser S 60  61  
Threonine, Thr T 74  75  
Tryptophan, Trp W 159 77, 117 , 130, 132, 170, 171 161  
Tyrosine, Tyr Y 136 91, 107 137  
Valine, Val V 72 41, 55, 69 73  
 
Table 1   List of immonium ions and the corresponding 15N labeled immonium ions.  As per Fallick et. al. 1993 and Hohmann 2008.  The 
column for the observed 15N related ions only displays those related ions that we have experimentally observed.   
 
Table 2. 15N DHDPS peptides screened from complex mixture by LC\MS\MS or NIIPe scan 
DHDPS Peptides m/z LC- MS/MS 
Triple Pre 
 (71,85,87) Pre 71 Pre 85 Pre 87 
AHVNFLLENNAQAIIVNGTTAESPTLTTDEKELILK 
 990 √   √  
ALGADAIMLITPYYNK 
 592  √ √ √  
EFQALYDAQQSGLDIQDQFKPIGTLLSALSVDINPIPIK 1447 √     
GGQGVISVIANVIPK 
 736    √  
LPLVSLEDTDTK 
 672   √   
LPVVLYNVPSR 
 636  √    
MTHLFEGVGVALTTPFTNNK 
 735   √ √ √ 
PIGTLLSALSVDINPIPIK 
 661  √ √ √ √ 
SALSVDINPIPIK 
 691     √ 
TNMTIEPETVEILSQHPYIVALK 
 885 √ √ √ √ √ 
TNNKINIEALK 
 636  √ √   
Total 3 5 6 6 4 
Total by summation of singles 9 
 
 
 
